GSK PLC
GS71
Company Profile
Business description
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Contact
79 New Oxford Street
LondonWC1A 1DG
GBRT: +44 2080475000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2026
Employees
68,629
Stocks News & Analysis
stocks
Will undervalued ASX share show progress in results?
Investors will get to see if the new strategy and capital management framework are working.
stocks
10 best US dividend aristocrats to buy now for 2026
These undervalued stocks with economic moats have increased their dividends for 25 consecutive years or more.
stocks
What to expect from the January Fed meeting
Central bankers are likely to hold interest rates steady, but Wall Street is focused on life after Powell.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,267.50 | 33.80 | -0.36% |
| CAC 40 | 8,152.82 | 21.67 | 0.27% |
| DAX 40 | 24,894.44 | 38.64 | -0.15% |
| Dow JONES (US) | 49,003.41 | 408.99 | -0.83% |
| FTSE 100 | 10,207.80 | 58.95 | 0.58% |
| HKSE | 27,126.95 | 361.43 | 1.35% |
| NASDAQ | 23,817.10 | 215.74 | 0.91% |
| Nikkei 225 | 53,083.79 | 249.75 | -0.47% |
| NZX 50 Index | 13,469.30 | 41.58 | -0.31% |
| S&P 500 | 6,978.60 | 28.37 | 0.41% |
| S&P/ASX 200 | 8,947.80 | 26.50 | -0.30% |
| SSE Composite Index | 4,139.90 | 0.01 | -0.00% |